Long-term drug treatment in multiple sclerosis: safety success and concerns.

Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf. 2020 Aug 01;: Authors: Jakimovski D, Vaughn CB, Eckert S, Zivadinov R, Weinstock-Guttman B Abstract INTRODUCTION: The portfolio of multiple sclerosis (MS) disease modifying treatments (DMTs) has significantly expanded over the past two decades. Given the life-long use of MS pharmacotherapy, understanding their long-term safety profiles is essential in determining suitable and personalized MS treatment. AREAS COVERED: In this narrative review, we summarize the short-, mid- and long-term safety profile of all currently available MS DMTs categories. In addition to the initial trial findings, safety outcomes derived from long-term extension studies (≥5-20 years) and safety-based prescription programs have been reviewed. In order to better understand the risk-benefit ratio for each particular DMT group, a short description of the DMT-based efficacy outcomes has been included. EXPERT OPINION: Long-term extension trials, large observational studies and real-world databases allow detection of rare and potentially serious adverse events. Two year-long trials are unable to fully capture the positive and negative effects of immune system modulation and reconstitution. DMT-based monitoring programs can provide greater insights regarding safe use of MS medications in different patient populations and clinical settings. During the p...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research